When Cell and Gene Therapies Surge to Market, How Resilient Will Your Cell Sourcing Infrastructure Be?
Nullam velit nulla commodo sem, at egestas nulla metus vel imperdiet aptent taciti ad litora torquent per.
Understanding Donor Characteristics to Improve Allogeneic Cell Therapy Outcomes for All
Can donor-reported characteristics, like race and ethnicity, impact data quality for allogeneic cell therapies? That’s one of the questions our expert panelists will discuss during our upcoming webinar. You’ll walk away with a better understanding of: Efficiencies in donor selection to reduce uncertainties about HLA matching and improve allogeneic cell therapy outcomes HLA complexity in cell source selection …
Understanding and leveraging cord blood bank capabilities and practices in cell therapy development
The cord blood banking industry has been around for over 30 years, focusing on acquiring units for use in hematopoietic stem cell transplant. Recent research indicates that cord blood can be a valuable source of naïve cells for cell therapy manufacturing. Cord blood banks are evolving their processes to accommodate the use of cord blood…
The Historical HLA Learning Curve
Human leukocyte antigens (HLAs), which are proteins found on the surface of most human cells, are fundamental to the success of matching potentially life-saving donors with patients in need of a blood stem cell transplant. Immune cells use HLAs to protect one’s own cells from invading microbes and viruses. A properly functioning immune system will…
Size Matters: Ensuring Donor Pool Sustainability and Cell Therapy Supply Chain Success When Scaling Up and Out
View this on-demand webinar to learn how to increase potential for long-term success and ensure donor pool sustainability in allogeneic and autologous programs. Discover the keys to enabling a smoother, faster transition to market and ultimately, access to more patients. Our expert panelists will cover: What to expect when transitioning from small trial sizes to…
Scalability Considerations When Using Cord Blood as an Allogeneic Starting Material
Learn why cord blood may be an excellent starting material for your therapy Cord blood has been used to provide life-saving treatments to patients for decades, but its full potential has not yet been tapped. Learn about scalability considerations when using cord blood. During this hour long on-demand webinar, our panelists discuss: Why it’s essential…
Optimizing Access to High-Quality, Standardized and Compliant Leukopaks for the Development and Commercialization of Allogeneic Therapies
Cellular starting material is the most critical component in the allogeneic cell therapy manufacturing process. Ensuring material access while maintaining quality, consistency and regulatory compliance are necessary throughout every stage of clinical development through commercialization. During this webinar, you will learn about: Factors to ensure streamlined access to high-quality, consistent starting material for allogeneic therapies…
Novel Allogeneic Cellular Therapies: Predictions for the Future
The ONE Forum 2021: On-demand session Over the last several years, there has been increasing global investment in the development of novel allogeneic cellular therapies. A recent study published by Nature Reviews Drug Discovery estimates that in 2021 over 400 novel allogeneic cellular therapies are under development across the globe, many of which are focused…
Navigating Scalability and Consistency in the Allogeneic Supply Chain
In this webinar, we focus on the scalability of donor starting material to support the growth and commercialization of allogeneic therapies. Throughout this discussion, we answer these questions on scalability and consistency in the allogeneic supply chain: What are the major gaps currently in the industry? How can we gain a better understanding of what…